Literature DB >> 16303100

Autoimmune mechanisms in children with systemic lupus erythematosus.

Dorothee Stichweh1, Virginia Pascual.   

Abstract

Although the pathogenesis of SLE remains poorly understood, there is consensus that it involves a combination of genetic, hormonal, and environmental factors. New technologies applied to genomic and gene expression studies have revealed novel gene mutations and cytokine alterations in this disease. Recently, advances in monoclonal antibodies and recombinant DNA technology have resulted in the development of new drugs to arrest disease progression and restore physiologic immune responses without major side effects. Clinical trials to test several of these novel therapies are currently underway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16303100     DOI: 10.1007/s11926-005-0045-4

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.686


  64 in total

Review 1.  Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE.

Authors:  George C Tsokos; Madhusoodana P Nambiar; Klaus Tenbrock; Yuang-Taung Juang
Journal:  Trends Immunol       Date:  2003-05       Impact factor: 16.687

2.  Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6.

Authors:  Gaetan Jego; A Karolina Palucka; Jean-Philippe Blanck; Cecile Chalouni; Virginia Pascual; Jacques Banchereau
Journal:  Immunity       Date:  2003-08       Impact factor: 31.745

3.  DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL.

Authors:  Mikhail B Litinskiy; Bernardetta Nardelli; David M Hilbert; Bing He; Andras Schaffer; Paolo Casali; Andrea Cerutti
Journal:  Nat Immunol       Date:  2002-08-05       Impact factor: 25.606

4.  Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes.

Authors:  M Koshy; D Berger; M K Crow
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

5.  Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.

Authors:  Kenneth C Kalunian; John C Davis; Joan T Merrill; Mark C Totoritis; David Wofsy
Journal:  Arthritis Rheum       Date:  2002-12

6.  Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus.

Authors:  E M Davas; A Tsirogianni; I Kappou; D Karamitsos; I Economidou; P C Dantis
Journal:  Clin Rheumatol       Date:  1999       Impact factor: 2.980

7.  Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients.

Authors:  Ann E Traynor; Walter G Barr; Robert M Rosa; Julianne Rodriguez; Yu Oyama; Steven Baker; Mary Brush; Richard K Burt
Journal:  Arthritis Rheum       Date:  2002-11

Review 8.  Immunopathology and the gene therapy of lupus.

Authors:  R A Mageed; G J Prud'homme
Journal:  Gene Ther       Date:  2003-05       Impact factor: 5.250

Review 9.  Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases.

Authors:  Timothy A Stewart
Journal:  Cytokine Growth Factor Rev       Date:  2003-04       Impact factor: 7.638

10.  Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes.

Authors:  B Dubois; B Vanbervliet; J Fayette; C Massacrier; C Van Kooten; F Brière; J Banchereau; C Caux
Journal:  J Exp Med       Date:  1997-03-03       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.